Advancing brain health is a strategic priority for Angelini Ventures; its early backing of CoMind has supported the translation of a novel concept to a promising product opportunity with the potential to deliver major benefits to patients
The follow-on investment builds on Angelini Ventures' co-lead participation in CoMind's 2023 Series A round reflecting continued confidence in the company's breakthrough neurotechnology platform
Rome, Italy, 20 October 2025 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces its participation in the latest $60 million funding round of CoMind, a UK-based neurotechnology company developing breakthrough optical sensing technology to revolutionise brain monitoring and treatment. The round was led by Plural, with participation from existing investors Angelini Ventures, Octopus Ventures and LocalGlobe, among others. To date, CoMind has raised a total of $102.5 million.
This follow-on investment builds on Angelini Ventures' co-lead participation in CoMind's 2023 Series A funding round of $27 million alongside Octopus Ventures and underscores Angelini Ventures' continued confidence in CoMind's technology platform and its potential to transform bedside brain monitoring.
The funds will support CoMind's pursuit of regulatory approval in the United States for the company's first product, CoMind One, the first device with the potential to non-invasively and continuously monitor brain blood flow, brain pressure, and other critical physiological parameters in a single measurement. In addition, the funds will enable completion of additional clinical trials, team expansion, and manufacturing partnerships.
CoMind One uses a low-power laser to transmit light through the scalp and skull into the brain ...
